Primeholly

Primeholly is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to the development of innovative peptide drugs. The company leverages a proprietary technology platform to design and optimize antimicrobial peptides (AMPs) that target multi-drug resistant pathogens by disrupting bacterial cell membranes. Its flagship product, PL-5, is a topical antimicrobial peptide currently undergoing Phase 3 clinical trials for the treatment of skin and soft tissue infections, including diabetic foot ulcers. Primeholly's pipeline also includes candidates for catheter-related infections and respiratory tract infections, aiming to provide alternatives to traditional antibiotics. The company has established integrated capabilities spanning drug discovery, clinical development, and GMP manufacturing at its facilities in Jiangsu.